Collaborations Pharmaceuticals
ApprovedCollaborations Pharmaceuticals applies a unique dual model of developing its own therapeutic pipeline while licensing its AI/ML software tools to external partners. The company has demonstrated success in securing non-dilutive government funding, primarily from the NIH and DOD, to advance its programs. Its most advanced asset is an enzyme replacement therapy for the ultra-rare, fatal CLN1 Batten disease, which has completed GMP manufacturing and is preparing for IND-enabling studies. The company's strategy combines internal R&D with a fee-for-service and software licensing business to fund its operations.
Private Company
Total funding raised: $480K
AI Company Overview
Collaborations Pharmaceuticals applies a unique dual model of developing its own therapeutic pipeline while licensing its AI/ML software tools to external partners. The company has demonstrated success in securing non-dilutive government funding, primarily from the NIH and DOD, to advance its programs. Its most advanced asset is an enzyme replacement therapy for the ultra-rare, fatal CLN1 Batten disease, which has completed GMP manufacturing and is preparing for IND-enabling studies. The company's strategy combines internal R&D with a fee-for-service and software licensing business to fund its operations.
Technology Platform
A proprietary suite of AI and machine learning software tools for generative molecular design, predictive ADME/Tox modeling, and data analysis, applied to accelerate drug discovery for rare and neglected diseases.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
In CLN1 Batten disease, the company faces no approved therapy competitors but may contend with other preclinical programs. In the AI drug discovery platform market, it competes with large public AI biotechs (e.g., Recursion, Exscientia) and software firms. Its differentiation lies in a niche rare disease focus, hands-on scientific expertise, and a proven grant-funding model.